Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021
February 23 2021 - 7:05AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing and delivering treatments that
restore and preserve vision for people with serious back of the eye
diseases, announced today that the Company will participate in two
upcoming investor conferences in March 2021:
Cowen 41st Annual Health Care ConferenceBlazing
New Paths in Clinical Development and Structure PanelTuesday, March
2, 2021 at 2:10 pm ET
33rd Annual ROTH Conference Ophthalmology
PanelTuesday, March 16, 2021 at 9:00 am ET
The panels will be available for attendees on
the conference websites. Management will be participating in live,
virtual one-on-one meetings with investors who are registered to
attend the conferences.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing and delivering
treatments that restore and preserve vision for people with serious
back of the eye diseases. Clearside’s proprietary SCS
Microinjector® targets the suprachoroidal space (SCS®) and offers
unique access to the macula, retina and choroid where
sight-threatening disease often occurs. The Company’s SCS injection
platform is an inherently flexible, in-office, non-surgical
procedure, intended to provide targeted delivery to the site of
disease and to work with both established and new formulations of
medications, as well as future therapeutic innovations. For more
information, please visit www.clearsidebio.com.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Sep 2023 to Sep 2024